Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.

被引：0

作者：

Jindal, Tanya

Alhalabi, Omar

Nguyen, Charles B.

Bakaloudi, Dimitra Rafailia

Nizam, Amanda

Bilen, Mehmet Asim

Basu, Arnab

Zakharia, Yousef

Milowsky, Matthew I.

Brown, Jason R.

Kilari, Deepak

Shah, Sumit

Emamekhoo, Hamid

Grivas, Petros

Hoimes, Christopher J.

Gupta, Shilpa

Bellmunt, Joaquim

Campbell, Matthew T.

Alva, Ajjai Shivaram

Koshkin, Vadim S.

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Univ Texas MD Anderson Canc Ctr Houston, Dept Genitourinary Med Oncol, Houston, TX USA

[3] Michigan Med, Ann Arbor, MI USA

[4] Univ Washington, Dept Med, Div Oncol, Seattle, WA USA

[5] Cleveland Clin, Cleveland, OH USA

[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA

[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[11] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI USA

[12] Stanford Canc Ctr, Stanford, CA USA

[13] Univ Wisconsin, Madison, WI USA

[14] Univ Washington, Div Hematol & Oncol, Seattle, WA USA

[15] Fred Hutchinson Canc Ctr, Seattle, WA USA

[16] Duke Univ, Duke Canc Inst, Durham, NC USA

[17] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[18] Dana Farber Canc Inst, Boston, MA USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA

[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

261-566-9263; 283-183-138-12099; 2; 3224; 3; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.651

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：651 / 651

页数：1

共 50 条

[21] Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
Minato, Akinori
Furubayashi, Nobuki
Tomoda, Toshihisa
Masaoka, Hiroyuki
Song, Yoohyun
Hori, Yoshifumi
Kiyoshima, Keijiro
Negishi, Takahito
Kuroiwa, Kentaro
Seki, Narihito
Tomisaki, Ikko
Nakamura, Motonobu
Harada, Kenichi
Fujimoto, Naohiro
ANTICANCER RESEARCH, 2024, 44 (08) : 3419 - 3426
[22] A CASE OF ENFORTUMAB VEDOTIN TOXICITY IN A PATIENT WITH ADVANCED UROTHELIAL CELL CARCINOMA
Grigsby, Charles
Thebert, Alexander
Pijut, Kyle
Woodward, Blake
Bastin, Melissa Thompson
Soper, Melissa
Fozzard, Andrew
CRITICAL CARE MEDICINE, 2024, 52
[23] Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin
Curran, Catherine
Adib, Elio
Kazakova, Vera
Grivas, Petros
Diamantopoulos, Leonidas Nikolaos
Alva, Ajjai Shivaram
Su, Christopher
Jain, Rohit K.
Tandon, Ankita
Necchi, Andrea
Marandino, Laura
Plastini, Trisha M.
Merchan, Jaime R.
Sonpavde, Guru
CLINICAL GENITOURINARY CANCER, 2022, 20 (01) : 11 - 16
[24] Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
Hanna, Kirollos S.
DRUGS, 2020, 80 (01) : 1 - 7
[25] Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
Wu, Qiuji
Qin, Yi
Liao, Weiting
Zhang, Mengxi
Yang, Yang
Zhang, Pengfei
Li, Qiu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[26] Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE
Nizam, A.
Zhang, L.
Jiang, C. Y.
Nguyen, C. B.
Bakaloudi, D. R.
Bilen, M. A.
Barata, P. M. Coelho
Zakharia, Y.
Milowsky, M. I.
Kilari, D.
Hoimes, C. J.
Khaki, A. R.
Emamekhoo, H.
Gupta, S.
Grivas, P.
Bellmunt, J.
Alva, A. S.
Campbell, M. T.
Alhalabi, O.
Koshkin, V. S.
ANNALS OF ONCOLOGY, 2024, 35 : S1142 - S1142
[27] Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
Kirollos S. Hanna
Drugs, 2020, 80 : 1 - 7
[28] FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Chang, Elaine
Weinstock, Chana
Zhang, Lijun
Charlab, Rosane
Dorff, Sarah E.
Gong, Yutao
Hsu, Vicky
Li, Fang
Ricks, Tiffany K.
Song, Pengfei
Tang, Shenghui
Waldron, Peter E.
Yu, Jingyu
Zahalka, Eias
Goldberg, Kirsten B.
Pazdur, Richard
Theoret, Marc R.
Ibrahim, Amna
Beaver, Julia A.
CLINICAL CANCER RESEARCH, 2021, 27 (04) : 922 - 927
[29] Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma.
Teo, Min Yuen
Ratna, Neha
Regazzi, Ashley Marie
Zimmerman, Danielle Elise
McHugh, Deaglan Joseph
Laccetti, Andrew Leonard
Xiao Han
Lee, Chung-Han
Aggen, David Henry
Funt, Samuel Aaron
Bajorin, Dean F.
Iyer, Gopa
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[30] Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis
Khosla, Harshit
Bhatt, Sita
Wang, Ming-Jin
Gignac, Gretchen
Mittal, Kriti
Patel, Jasmine
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (05) : 941 - 944

← 1 2 3 4 5 →